Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Molecular Insight Pharmaceuticals, Inc. (MIPI)
|
Add to portfolio |
|
|
|
| Price: |
$0.18
| | Metrics |
| OS: |
25.3
|
M
| |
|
|
| Market cap: |
$4.55
|
M
| |
|
|
|
Net cash:
|
$23.2
|
M
| |
$0.92
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| Revenues | 5.5 | 0.5 | 0.7 | 16.6 | 8.7 | 5.3 | 2.7 | 2,217.0 |
| Revenue growth | 1057.9% | -35.1% | -95.6% | 92.3% | 63.3% | 96.2% | -99.9% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 26.8 | 19.9 | 8.9 | 4.0 | 7,676.9 |
| Gross profit | 5.5 | 0.5 | 0.7 | -10.2 | -11.2 | -3.6 | -1.3 | -5,459.9 |
| Gross margin | 99.4% | 100.0% | 100.0% | -61.4% | -129.8% | -68.0% | -49.6% | -246.3% |
| General and administrative | 19.8 | 20.9 | 14.8 | 8.6 | 10.0 | 3.1 | 1.2 | 1,333.7 |
| EBIT | -46.3 | -61.9 | -57.7 | -26.5 | -18.6 | -8.3 | -3.3 | -7,052.7 |
| EBIT margin | -842.1% | -13047.3% | -7893.4% | -159.4% | -215.5% | -157.3% | -122.8% | -318.1% |
| Pre-tax income | -66.5 | -81.3 | -59.8 | -27.3 | -18.3 | -8.3 | -3.3 | -7,083.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -0.1 | -0.1 | -0.1 | -32.2 | 0.0 | 0.0 | 0.0 | -7.1 |
| Net margin | -1.2% | -17.1% | -8.4% | -193.7% | -0.3% | -0.2% | -0.1% | -0.3% |
| |
| Diluted EPS | ($2.64) | ($3.25) | ($2.65) | ($7.18) | ($5.30) | ($2.55) | ($1.13) | ($0.63) |
| Shares outstanding (diluted) | 0.0 | 0.0 | 0.0 | 4.5 | 0.0 | 0.0 | 0.0 | 11.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|